|COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring.|
The Ras pathway in cancer therapy
If you have a question about this talk, please contact Kate Davenport.
Note unusual day
K-Ras genes and N-Ras are frequently activated in cancer. Attempts to develop drugs that target mutant Ras have so far been unsuccessful. The reasons for these failures, and possible solutions based on new approaches, will be discussed. Drugs that inhibit Raf have failed to show clinical benefit in Ras-mutant tumors. In contrast, they paradoxically induce the Raf MAPK pathway in these cells. This, we propose, is because Raf is negatively regulated by auto-phosphorylation, so that Raf inhibitors relieve auto-phosphorylation before they inhibit MEK phosphorylation. K-Ras is activated far more frequently than N-Ras or H-Ras in human cancers. K-Ras, but not H-Ras activates a set of genes which are involved in stem cell phenotypes,. K-Ras is able to promote multiple stem cell characteristics in vitro and in vivos. These data may explain why cancer cells driven by K-Ras are especially difficult to treat and offer new opportunities for therapeutic intervention
This talk is part of the Cancer Research UK Cambridge Institute Seminars in Cancer series.
This talk is included in these lists:
Note that ex-directory lists are not shown.
Other listsPeterhouse Theory Group Nanoscience Centre Seminar Series Cambridge University Armenian Society
Other talksExtracting Uplift Rate Histories From River Profiles: Examples from Africa, North America and Australia Asymptotic Approximations for High-Frequency Sound Generated by Aerofoils in Flow The Ehrenpreis principle: from ODEs to PDEs Ephemeral Matter Induced Pluripotent Stem Cells: Production and Utility in Regenerative Medicine and Other Applications An introduction to Origins of the Afro Comb exhibition